Locations
Paris, France · Europe
industry
Health · Biotechnology · DeepTech
Size
51-200 employees
Stage
Series A
founded in
2012
Depixus is undertaking commercial development of a technology for the fast, accurate, and inexpensive extraction of genetic and epigenetic information from single molecules of DNA and RNA. The technology is known as SIMDEQ (SIngle-molecule Magnetic DEtection and Quantification). It was initially developed in the laboratory of Vincent Croquette, David Bensimon, and Jean-François Allemand at École Normale Supérieure (ENS), one of France’s leading ‘grandes écoles’. SIMDEQ has a wide range of potential applications across the life-science and medical industries. Using the SIMDEQ platform, it will be possible to identify, count, fully sequence, and epitype many millions of individual molecules of DNA at a high speed and accuracy. Substantial validation of our technology has already been completed and the first steps towards platform optimisation and commercialisation are underway.
Something looks off?